BACKGROUND AND PURPOSE: Sphingosine 1-phosphate (S1P) selectively and potently constricts isolated cerebral arteries, but this response has not been pharmacologically characterized. EXPERIMENTAL APPROACH: The receptor subtype(s) involved in S1P-induced cerebrovascular constriction were characterized using genetic (S1P(2) and S1P(3) receptor null mice) and pharmacological tools (phospho-FTY720, a S1P(1/3/4/5) receptor agonist; SEW2871, a S1P(1) receptor agonist, JTE-013, a S1P(2) receptor antagonist, VPC23019, a S1P(1/3) receptor antagonist). Isolated basilar or peripheral (femoral, mesenteric resistance) arteries, from either rat or mouse, were studied in a wire myograph. KEY RESULTS: S1P concentration-dependently constricted basilar artery in rat, wild-type (WT) and S1P(2) null mice, but barely affected vascular tone in S1P(3) null mice. Vasoconstriction to U46619 (a thromboxane analogue) or to endothelin-1 did not differ between WT, S1P(2) and S1P(3) null mice. JTE-013 inhibited not only S1P-induced vasoconstriction, but also KCl-, U46619- and endothelin-1-induced constriction. This effect was observed in WT as well as in S1P(2) null mice. VPC23019 increased the concentration-dependent vasoconstriction to S1P in both rat and mouse basilar arteries with intact endothelium, but not in rat basilar artery without endothelium. Phospho-FTY720 concentration-dependently constricted rat basilar arteries, but not femoral or mesenteric resistance arteries, while SEW2871 did not induce any response in the same arteries. CONCLUSIONS AND IMPLICATIONS: S1P constricts cerebral arteries through S1P(3) receptors. The purported S1P(2) receptor antagonist JTE-013 does not appear to be selective, at least in rodents. Enhancement of S1P-induced contraction by VPC23019 might be related to blockade of S1P(1) receptors and NO generation.
BACKGROUND AND PURPOSE:Sphingosine 1-phosphate (S1P) selectively and potently constricts isolated cerebral arteries, but this response has not been pharmacologically characterized. EXPERIMENTAL APPROACH: The receptor subtype(s) involved in S1P-induced cerebrovascular constriction were characterized using genetic (S1P(2) and S1P(3) receptor null mice) and pharmacological tools (phospho-FTY720, a S1P(1/3/4/5) receptor agonist; SEW2871, a S1P(1) receptor agonist, JTE-013, a S1P(2) receptor antagonist, VPC23019, a S1P(1/3) receptor antagonist). Isolated basilar or peripheral (femoral, mesenteric resistance) arteries, from either rat or mouse, were studied in a wire myograph. KEY RESULTS:S1P concentration-dependently constricted basilar artery in rat, wild-type (WT) and S1P(2) null mice, but barely affected vascular tone in S1P(3) null mice. Vasoconstriction to U46619 (a thromboxane analogue) or to endothelin-1 did not differ between WT, S1P(2) and S1P(3) null mice. JTE-013 inhibited not only S1P-induced vasoconstriction, but also KCl-, U46619- and endothelin-1-induced constriction. This effect was observed in WT as well as in S1P(2) null mice. VPC23019 increased the concentration-dependent vasoconstriction to S1P in both rat and mouse basilar arteries with intact endothelium, but not in rat basilar artery without endothelium. Phospho-FTY720 concentration-dependently constricted rat basilar arteries, but not femoral or mesenteric resistance arteries, while SEW2871 did not induce any response in the same arteries. CONCLUSIONS AND IMPLICATIONS: S1P constricts cerebral arteries through S1P(3) receptors. The purported S1P(2) receptor antagonist JTE-013 does not appear to be selective, at least in rodents. Enhancement of S1P-induced contraction by VPC23019 might be related to blockade of S1P(1) receptors and NO generation.
Authors: H Okazaki; N Ishizaka; T Sakurai; K Kurokawa; K Goto; M Kumada; Y Takuwa Journal: Biochem Biophys Res Commun Date: 1993-02-15 Impact factor: 3.575
Authors: Hong Liu; Rachelle E Toman; Sravan K Goparaju; Michael Maceyka; Victor E Nava; Heidi Sankala; Shawn G Payne; Meryem Bektas; Isao Ishii; Jerold Chun; Sheldon Milstien; Sarah Spiegel Journal: J Biol Chem Date: 2003-06-30 Impact factor: 5.157
Authors: Jerzy-Roch Nofer; Markus van der Giet; Markus Tölle; Iza Wolinska; Karin von Wnuck Lipinski; Hideo A Baba; Uwe J Tietge; Axel Gödecke; Isao Ishii; Burkhard Kleuser; Michael Schäfers; Manfred Fobker; Walter Zidek; Gerd Assmann; Jerold Chun; Bodo Levkau Journal: J Clin Invest Date: 2004-02 Impact factor: 14.808
Authors: Parker C Wilson; Wayne R Fitzgibbon; Sara M Garrett; Ayad A Jaffa; Louis M Luttrell; Michael W Brands; Hesham M El-Shewy Journal: Mol Endocrinol Date: 2015-04-14
Authors: M Germana Sanna; Kevin P Vincent; Emanuela Repetto; Nhan Nguyen; Steven J Brown; Lusine Abgaryan; Sean W Riley; Nora B Leaf; Stuart M Cahalan; William B Kiosses; Yasushi Kohno; Joan Heller Brown; Andrew D McCulloch; Hugh Rosen; Pedro J Gonzalez-Cabrera Journal: Mol Pharmacol Date: 2015-10-22 Impact factor: 4.436